Search results
TB has reclaimed its place as the world’s biggest infectious killer – but are its days numbered?
Daily Telegraph· 4 days agoAs patients’ immune systems were weakened by the new disease, there was a surge in TB. HIV caused 55...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 4 days agoWASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...
ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance...
WTRF Wheeling· 3 days agoCelltrion USA announced today positive two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for ZYMFENTRA™ (infliximab-dyyb) in adult patients with moderately to severely ...
FBI gate crash suspect granted bond — with conditions
Atlanta Journal-Constitution· 7 days agoA South Carolina man accused of breaching the gate at the FBI Atlanta offices in April was granted...
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...
KTLA-TV Los Angeles· 1 day agoUCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX ...
ADA2 regulates inflammation and hematopoietic stem cell emergence via the A2bR pathway in zebrafish...
Nature· 2 days agoA DADA2 zebrafish model with cecr1b deficiency was generated. Characterization of hematopoietic processes revealed a role of Cecr1b in regulating inflammation and hematopoietic stem cell production through the A2br-mediated adenosine signaling.
Word of the Day: Don't Say "Covid Pandemic." Say "Covid Syndemic"! | naked capitalism
Naked Capitalism· 5 days ago"'Tis a mystery," except not!
WHO report shows sexually transmitted infections are climbing
Center for Infectious Disease Research and Policy· 2 days agoA new report from the World Health Organization (WHO) shows that 2 years into a global effort to...
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved...
WTRF Wheeling· 3 days agoIn Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically ...